Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib-Reference-Cited by-同舟云学术

Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib

Published:2021-02-15 Issue: Volume: Page:
ISSN:
Container-title:Poster Spotlight Session Abstracts
language:
Short-container-title:

Author:

Tripathy Debu,Im Seock-Ah,Colleoni Marco,Franke Fabio,Bardia Aditya,Harbeck Nadia,Hurvitz Sara,Chow Louis,Sohn Joohyuk,Lee Keun Seok,Campos-Gomez Saul,Vazquez Rafael Villanueva,Jung Kyung Hae,Babu K Govind,Wheatley-Price Paul,De Laurentiis Michelino,Im Young-Hyuck,Kümmel Sherko,El-Saghir Nagi,Liu Mei-Ching,Kaur Sharonjeet,Gasch Claudia,Wang Craig,Wang Yongyu,Chakravartty Arunava,Lu Yen-Shen

Publisher

American Association for Cancer Research

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation;Frontiers in Oncology;2024-07-24

2. Beyond the median: Estimating survival times for patients starting endocrine therapy for estrogen receptor‐positive, metastatic breast cancer from recent randomized trials;Asia-Pacific Journal of Clinical Oncology;2024-06-16

3. CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs;Geburtshilfe und Frauenheilkunde;2024-05

4. Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study;JCO Global Oncology;2024-04

5. Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study;Journal of Modern Oncology;2024-03-05